期刊文献+

蒽环类药物联合曲妥珠单抗同步应用于乳腺癌的辅助治疗临床效果

原文传递
导出
摘要 目的:探讨蒽环类药物联合曲妥珠单抗同步应用于乳腺癌辅助治疗临床效果。方法:选取2010年2月-2013年6月我院收治89例乳腺癌患者随机分为同步治疗组和序贯治疗组,同步治疗组采用蒽环类药物联合曲妥珠单抗同步治疗,序贯治疗组采用蒽环类药物联合曲妥珠单抗序贯治疗。比较两组患者治疗效果、对心脏毒副作用、生活质量及1年生存率。结果:同步治疗组治疗有效率为93.33%明显高于序贯治疗组75.00%治疗有效率,两组比较有统计学意义(P〈0.05);同步治疗组和序贯治疗组治疗1年后均无患者死亡,两纽患者生存率均为100%,比较无统计学意义(P〉0.05);同步治疗组和治疗纽治疗前、治疗后3月、6月、12月LVEF比较均无统计学意义(P〉0.05);同步治疗组生活质量评分中生理功能、生理职能、健康状况、社会功能及情感职能评分均高于序贯治疗组,两组间各值比较有统计学意义(P〈0.05)结论:蒽环类药物联合曲妥珠单抗同步治疗乳腺癌相对序贯疗法可提高患者治疗效果、提高生活质量,并对心脏副作用较小,具有较高治疗效果和用药安全性,值得在临床推广应用。
出处 《医学与社会》 2015年第B06期232-233,共2页 Medicine and Society
  • 相关文献

参考文献6

二级参考文献58

  • 1MAURI D, PAVLIDIS N, IOANNIDIS J P, et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta- analysis [J].J Natl Cancer Inst, 2005, 97: 188-194. 被引量:1
  • 2VAN DER HAGE J A, VAN DE VELDE C J, TUBIANA- HULIN M, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 [J].J Clin Oncol, 2001, 19: 4224-37. 被引量:1
  • 3DEMONTY G, BERNARD-MARTY C, PUGLISI F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer [ J ] . Eur J Cancer, 2007, 43: 497-509. 被引量:1
  • 4LAZARIDIS G, PENTHEROUDAKIS G, PAVLIDIS N. Integrating trastnzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety [ J ] . Crit Rev Oncol Hematol, 2008, 66: 31-41. 被引量:1
  • 5VON MINCKWITZ G, KAUFMANN M, KUMMEL S, et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane + trastuzumab containing chemotherapy [ J ] . Cancer Res, 2009, 69(Suppl 2): 79. 被引量:1
  • 6LAZARIDIS G, PENTHEROUDAKIS G, PAVLIDIS N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety [ J ] . Crit Rev Oncol Hematol, 2008, 66: 31-41. 被引量:1
  • 7Slamon D J, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science, 1987, 235 : 177-182. 被引量:1
  • 8Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344:783- 792. 被引量:1
  • 9Marry M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274. 被引量:1
  • 10Schaller G, Fuchs I, Gonsch T, et al. Phase Ⅱ study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol, 2007, 25:3246-3250. 被引量:1

共引文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部